论文部分内容阅读
骨肉瘤的综合治疗极大地提高了骨肉瘤患者5年生存率,但是仍然有许多患者死于手术后肺部转移。研究发现原发肿瘤自身 具有抑制转移瘤生长的作用,这种现象不依赖于任何特异的免疫反应,被称作伴发性肿瘤抵抗(concomitant tumour resistance, CTR)。CTR发生机制目前不详。O’Reilly等研究指出原发肿瘤分泌的抗血管生成因子抑制肺部转移灶的生长,是CTR产生的主要原因。为了证实临床上也存在这种现象,该文作者在1999年至
The comprehensive treatment of osteosarcoma greatly improves the 5-year survival rate of patients with osteosarcoma, but there are still many patients died of lung metastasis after surgery. The study found that the primary tumor itself has the effect of inhibiting the growth of metastases, which is not dependent on any specific immune response and is referred to as concomitant tumor resistance (CTR). CTR mechanism is currently unknown. O’Reilly and other studies have pointed out that the primary tumor secretion of anti-angiogenic factors inhibit the growth of lung metastases, is the main cause of CTR. In order to confirm the clinical existence of this phenomenon, the author in 1999 to